Global law firm White & Case LLP has advised the German chemical and pharmaceutical company Merck KGaA on the agreement by its Life Science business, Merck Millipore, to acquire the worldwide rights to an innovative protein detection technology.
Under the terms of the agreement, Merck Millipore will have exclusive rights to further develop and commercialize Singulex's Single Molecule Counting (SMC) technology for research applications worldwide. Merck Millipore will pay Singulex an upfront payment, royalties and additional payments based upon achievement of certain commercial milestones.
The SMC technology is a novel, patented technology to achieve ultra-high sensitivity protein detection for clinical diagnostics and scientific discovery. California-based Singulex Inc., the developer and leading provider of this technology, is the seller of the rights.
Headquartered in Billerica, Massachusetts, Merck Millipore is the Life Science subsidiary of Merck KGaA and offers solutions and services for research, development and production of biotechnology and pharmaceutical drug therapies.
The White & Case team which advised on the transaction was led by partners Stefan Koch (Frankfurt) and Eric Hwang (Silicon Valley) with support from partners Frank-Karl Heuchemer (Frankfurt), Jane Plomley (Washington, D.C.) and Stephen Ravenscroft (London) as well as counsel Tal Marnin (New York).
For more information please speak to your local media contact.